
|Videos|June 28, 2016
The Impact of CheckMate-205 for Patients With Classical Hodgkin Lymphoma
Author(s)Anas Younes, MD
Anas Younes, MD, medical oncologist at Memorial Sloan Kettering Cancer Center in New York, discusses the potential impact of CheckMate-205 nivolumab as a treatment for patients with Hodgkin lymphoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
3
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
4
IMNN-001 Plus Chemo Cuts MRD Rate in Frontline Ovarian Cancer
5































